Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Why Acadia Pharmaceuticals (ACAD) Stock is a Compelling Investment Case

If you are looking for the best ideas for your portfolio you may want to consider some of Mott Capital’s top stock picks. Mott Capital, an investment management firm, is bullish on Acadia Pharmaceuticals Inc (NASDAQ:ACAD) stock. In its Q4 2019 investor letter – you can download a copy here – the firm discussed its investment thesis on Acadia Pharmaceuticals Inc (NASDAQ:ACAD) stock. Acadia Pharmaceuticals Inc (NASDAQ:ACAD) is a biopharmaceutical company based in California. The stock is up 32% since the Mott Capital’s pitch in January 2020, which suggests the investment firm was right in its decision. On a year-to-date basis, Acadia Pharmaceuticals Inc (NASDAQ:ACAD) stock has risen by 32.2%.

On January 23, 2020, Mott Capital had released its Q4 2019 Investor Letter. Mott Capital said that Acadia Pharmaceuticals Inc (NASDAQ:ACAD) stock rose 164% in 2019. The investment firm added that it was the best performing stock in the portfolio.

In 2019, the Mott Capital Thematic Growth Composite recorded a return of 35.85% (net of fees) as compared to 31.45% of the S&P 500 Index (total return).

Let’s take a look at comments made by Mott Capital about Acadia Pharmaceuticals Inc (NASDAQ:ACAD) in the letter.

“Acadia (ACAD) was the best performing stock in 2019 in the portfolio, rising by more than 164%. The biggest jump happened at the end of the third quarter when the company announced the successful completion of their dementia-related psychosis trial. As a result, the company plans to submit a supplemental new drug application (sNDA) to the FDA by the summer of 2020. Given that Pimavanserin has a breakthrough therapy designation, I believe there is an excellent chance the drug receives approval before the end of 2020.”

Countries With Highest Medical Research Spending

In Q1 2020, the number of bullish hedge fund positions on Acadia Pharmaceuticals Inc (NASDAQ:ACAD) stock decreased by about 18% from the previous quarter (see the chart here), so a number of other hedge fund managers don’t seem to agree with Acadia’s growth potential. Our calculations showed that Acadia Pharmaceuticals Inc (NASDAQ:ACAD) isn’t ranked among the 30 most popular stocks among hedge funds.

The top 10 stocks among hedge funds returned 185% since the end of 2014 and outperformed the S&P 500 Index ETFs by more than 109 percentage points. We know it sounds unbelievable. You have been dismissing our articles about top hedge fund stocks mostly because you were fed biased information by other media outlets about hedge funds’ poor performance. You could have doubled the size of your nest egg by investing in the top hedge fund stocks instead of dumb S&P 500 ETFs. Below you can watch our video about the top 5 hedge fund stocks right now. All of these stocks had positive returns in 2020.

Video: Top 5 Stocks Among Hedge Funds

At Insider Monkey we scour multiple sources to uncover the next great investment idea. There is a lot of volatility in the markets and this presents amazing investment opportunities from time to time. For example, this trader claims to deliver juiced up returns with one trade a week, so we are checking out his highest conviction idea. A second trader claims to score lucrative profits by utilizing a “weekend trading strategy”, so we look into his strategy’s picks. We read hedge fund investor letters and listen to stock pitches at hedge fund conferences. We recently recommended several stocks partly inspired by legendary Bill Miller’s investor letter. Our best call in 2020 was shorting the market when the S&P 500 was trading at 3150 in February after realizing the coronavirus pandemic’s significance before most investors. You can subscribe to our free enewsletter below to receive our stories in your inbox:

Disclosure: None. This article is originally published at Insider Monkey.